NSW2031 - Randwick - Scientia Clinical Research Ltd (COMPLETED)2065 - St Leonards - GenesisCare North Shore Private Hospital (COMPLETED)2109 - North Ryde - Macquarie University Hospital (COMPLETED)2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (COMPLETED)2170 - Liverpool - Sydney South West Private Hospital (COMPLETED)2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (COMPLETED)

VIC3199 - Frankston - Peninsula Health Frankston Hospital (COMPLETED)

QLD4215 - Southport - Gold Coast Private Hospital (COMPLETED)

WA6009 - Nedlands - One Clinical Research (COMPLETED)

NCT05176483

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology or Other Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors (STELLAR-002)

2640 - Albury - Border Medical Oncology Research Unit (WITHDRAWN)

NCT05168566

A Multicenter, Open-label, Phase IIb Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I) (SZCT-2020-06)

NCT05150691

A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients With Advanced/Metastatic Solid Tumors (DB-1303-O-1001)

NCT05086692

A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors (ABILITY-1)

NCT04879329

A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination With Pembrolizumab in Subjects With Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2 (RC48G001)

NCT03486873

A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab (3475-587)

2050 - Camperdown - Royal Prince Alfred Hospital - A.W. Morrow Gastroenterology and Liver Centre (COMPLETED)

4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (COMPLETED)4120 - Greenslopes - Greenslopes Private Hospital (COMPLETED)

NCT02582697

Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours (P3BEP)

3021 - St Albans - Western Health - Sunshine Hospital (WITHDRAWN)

NZ.9016 - Dunedin - Dunedin Hospital (WITHDRAWN)

ACTRN12626000289314

Part C: A Phase 1b, open-label, non-randomised, multicentre dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of AXA-042 monotherapy in subjects with advanced solid tumours.

NCT06199908

First-in-Human, Phase 1 Study of AMT-562 in Patients With Advanced Solid Tumors (AMT-562-01)

PD-1/PD-L1	26%
PD-1	22%
EGFR	11%
KRAS	11%
ERBB2	11%
MET	8%
oestrogen axis	7%
androgen axis	7%
VEGFR2	6%
ER	6%
AR	6%
AXL	5%
VEGF	5%
Trop2	5%
CYP17A1	5%
Nectin4	4%
HIF2a	4%
PD-L1	4%
CDK4	4%
ERBB3	4%
PARP	4%
B7H3	4%
CYP11A1	4%
MER	3%
CTLA4	3%
KIT	3%
RET	3%
ROS1	3%
VEGFR	3%
CDK6	3%
CD44v9	2%
VEGFA	2%
FGFR	2%
FGFR3	2%
CD19	2%
CD22	2%
CD20	2%
PSMA	2%
B7H4	2%
SMO	2%
LAG3	2%
HDAC6	1%
LSD1	1%
BCMA	1%
cereblon	1%
HDAC	1%
CD70	1%
PI3Kalpha	1%
FAK	1%
CALR	1%
Bcl2	1%
CCR8	1%
BTK	1%
CD79b	1%
MALT1	1%
KAT6	1%
KAT6A	1%
ITGB6	1%
4-1BB	1%
p95ERBB2	1%
HRAS G12C	1%
NRAS G12C	1%
FGFR2	1%
FGFR2b	1%
TF	1%
ER alpha	1%
CDH17	1%
PARP1-selective	1%
CDK4 selective	1%
HPK1	1%
CD47	1%
MUC18	1%
ERK	1%
DNA-dependent protein kinase	1%
CDK2	1%
KLK2	1%
CLDN18.2	1%
IL-2	1%
TLR2/TLR6	1%

ARTICANZ - Beta (ver 0.91)

Search results

Filters